경구 유발검사로 진단된 acebrophylline에 의한 전신성 고정약진
Acebrophylline-induced generalized fixed drug eruption confirmed by an oral provocation test
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The diagnosis of fixed drug eruption is straightforward because of characteristic findings, including recurrence of similar lesions at the same site and healing with residual hyperpigmentation. However, generalized or multiple fixed drug eruption, a rare variant form, can be a diagnostic challenge. Acebrophylline is a widely prescribed oral bronchodilator with mucosecretolyic and anti-inflammatory activity and is known to be relatively safe. A 34-year-old woman presented with recurrent numerous erythematous patches after ingestion of cold medications containing clarithromycin, loxoprofen, acebrophylline, and pseudoephedrine. Skin biopsy results showed vacuolar degeneration of the basal cell layer, scattered necrotic keratinocytes in the epidermis, and perivascular lymphohistiocytic infiltration in the upper dermis. A patch test showed negative results. However, in an oral challenge with acebrophylline 3 hours later, lesions reappeared at the same sites. To the best of our knowledge, this is the first case report of acebrophylline-induced generalized fixed drug eruption.
Abstract
The diagnosis of fixed drug eruption is straightforward because of characteristic findings, including recurrence of similar lesions at the same site and healing with residual hyperpigmentation. However, generalized or multiple fixed drug eruption, a rare variant form, can be a diagnostic challenge. Acebrophylline is a widely prescribed oral bronchodilator with mucosecretolyic and anti-inflammatory activity and is known to be relatively safe. A 34-year-old woman presented with recurrent numerous erythematous patches after ingestion of cold medications containing clarithromycin, loxoprofen, acebrophylline, and pseudoephedrine. Skin biopsy results showed vacuolar degeneration of the basal cell layer, scattered necrotic keratinocytes in the epidermis, and perivascular lymphohistiocytic infiltration in the upper dermis. A patch test showed negative results. However, in an oral challenge with acebrophylline 3 hours later, lesions reappeared at the same sites. To the best of our knowledge, this is the first case report of acebrophylline-induced generalized fixed drug eruption.
참고문헌 (20)
- Ozkaya E, "Fixed drug eruption: state of the art", J Dtsch Dermatol Ges, 6, pp.181~188 (2008)
- Goldrub N, "Therapeutic activity and tolerability profile of acebrophylline", Adv Ther, 9, pp.107~115 (1992)
- Kuriachan S, "Acebrophylline-induced angioedema", Indian J Pharmacol, 47, pp.219~220 (2015)
- Brocq L, "Eruption erythémato-pigmentéefixé due à l’antipyrine", Ann Dermatol Syphiligr, 5, pp.308~313 (1894)
- Lee AY, "Fixed drug eruptions. Incidence, recognition, and avoidance", Am J Clin Dermatol, 1, pp.277~285 (2000)
- Sawada Y, "Generalized fixed drug eruption caused by pazufloxacin", Acta Derm Venereol, 91, pp.600~601 (2011)
- Can C, "Generalized fixed drug eruption in a child due to trimethoprim", sulfamethoxazole, 2014, pp.25, 413~415
- Lipowicz S, "Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis", Br J Dermatol, 168, pp.726~732 (2013)
- Shear NH, "Fitzpatrick’s dermatology in general medicine", pp.359~360 (2007), McGraw-Hill
- 정재우, "Clinical Features of Fixed Drug Eruption at a Tertiary Hospital in Korea", Allergy, Asthma & Immunology Research, 6(5), pp.415~420 (2014), 대한천식알레르기학회
- Heng YK, "An update of fixed drug eruptions in Singapore", J Eur Acad Dermatol Venereol, 29, pp.1539~1544 (2015)
- Mizukawa Y, "In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption", Br J Dermatol, 158, pp.1230~1238 (2008)
- Choi HJ, "Possible role of Fas", Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption, 2006, pp.154, 419~425
- Cho YT, "Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome", toxic epidermal necrolysis by immunohistopathological features, 2014, pp.70, 539~548
- Dharamsi FM, "Bullous fixed drug eruption masquerading as recurrent Stevens Johnson syndrome", J Emerg Med, 48, pp.551~554 (2015)
- Elm MK, "Multifocal, fixed-drug eruption masquerading as recurrent erythema multiforme", J Drugs Dermatol, 11, pp.244~246 (2012)
- Sowden JM, "Multifocal fixed drug eruption mimicking erythema multiforme", Clin Exp Dermatol, 15, pp.387~388 (1990)
- Inserra DW, "Erythema multiforme-like fixed drug eruption", Cutis, 44, pp.223~225 (1989)
- Yoo SH, "Nonpigmenting fixed drug eruption to etodolac", Korean J Dermatol, 37, pp.673~675 (1999)
- Shiohara T, "Fixed drug eruption: pathogenesis and diagnostic tests", Curr Opin Allergy Clin Immunol, 9, pp.316~321 (2009)